Close

PCT to provide development, manufacturing services to Adaptimmune

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Fluid Path Integrity: Ensuring Purity in Biomanufacturing

In the high-stakes arena of biomanufacturing, where tiny contaminants...

GMP Fluid Handling: Regulatory Compliance Explained

Fluid Handling in GMP Manufacturing: The Essence of Regulatory...

Single-Use Technologies in Biopharma Transform Manufacturing

The biopharmaceutical sector is being revolutionized by the demand...

Advances in Aseptic fluid transfer solutions

Sterility and Cross-Contamination: The Cornerstones of Modern Biopharma Manufacturing Biopharmaceutical...

Progenitor Cell Therapy (PCT), a subsidiary of NeoStem, has signed an agreement to provide cell product development and manufacturing services for Adaptimmune’s clinical trials.

Adaptimmune will make use of PCT services in the development of its NYESO-1c259-T cell therapy targeting various oncology indications.

Adaptimmune chief executive officer James Noble said, “With our sights set on future pivotal trials for our T cell therapy products, we have invested significant effort towards establishing capabilities within Adaptimmune that support expansion of our clinical platform in terms of both scale and compliance with FDA requirements beyond phase I/II.”

PCT facility in Allendale, New Jersey, will provide transfer and qualification services essential for the NYESO-1c259-T cell therapy product manufacturing process following manufacturing of the product.

PCT president and chief scientific officer Robert Preti said, “Given our extensive experience with technology transfer, process qualification and GMP manufacturing, we feel PCT will be an asset to Adaptimmune as it develops its product for the U.S. commercial market.”

Latest stories